PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Personalis, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$15.88+0.23 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.67B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
22.7%−2.9 pts over 5 years
Operating margin
-126.4%−72.8 pts over 5 years
Net margin
-116.7%−64.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -17.7% | +2.3% | -2.4% | – | |
| Gross profit | -41.2% | +5.7% | -4.7% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -27.4% | -35.0% | |
| Return on assets | – | -20.5% | -26.9% | |
| Current ratio | – | 5.43 | 6.76 | |
| Interest coverage | – | -21073.0× | -429.5× | |
| Capex to revenue | – | 4.1% | 6.5% | |
| Diluted shares | – | 34M | 89M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Personalis generated $317.42M from operations and spent $78.00M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$317.42M
Used
$78.00M
Capital expenditure$78.00M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-116.7%
×Asset turnover0.23×
×Equity multiplier1.30×
=Return on equity, FY2025-35.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -116.7% | 0.23× | 1.30× | -35.0% |
| FY2024 | -96.1% | 0.34× | 1.49× | -48.9% |
| FY2023 | -147.4% | 0.28× | 1.49× | -62.3% |
| FY2022 | -174.2% | 0.19× | 1.30× | -42.9% |
| FY2021 | -76.3% | 0.27× | 1.27× | -25.8% |
| FY2020 | -52.5% | 0.39× | 1.33× | -27.4% |
| FY2019 | -38.5% | 0.66× | 658.81× | -16611.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$81.27M
- Cash generatingOperating cash flow above zero-$74.95M
- Return on assets improvedROA up on the prior year-36.1% → -30.1%
- Earnings backed by cashOperating cash flow above net income-$74.95M vs -$81.27M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.52 → 6.76
- No dilutionShare count did not rise59M → 89M
- Gross margin improvedGross margin up on the prior year31.70% → 22.65%
- More efficientAsset turnover rose0.38 → 0.26